Parathormon, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients

Ren Fail. 2001 Jan;23(1):115-26. doi: 10.1081/jdi-100001291.


Clinical and experimental data suggest that Parathormon (PTH), calcium, and phosphorus participate in left ventricular hypertrophy (LVH) and affect myocardial contractility in end-stage renal disease. Cellular calcium overload and interstitial fibrosis induced by PTH may lead to impairment of left ventricular diastolic function. Hyperphosphatemia is an independent risk of cardiovascular mortality in dialysis patients. The aim of the study was to estimate the influence of PTH and calcium-phosphorus metabolism on left ventricular structure and function in hemodialysis patients, without hypertension and antihypertensive drug therapy (SBP = 126.2 +/- 11.1 DBP = 75.8 +/- 6.5 mmHg). Echocardiographic findings in a group of 22 normotensive HD patients had been compared to 43 hypertensive HD patients. Relationships between PTH, calcium-phosphorus metabolism and echocardiography in normotensive group were then evaluated. Left ventricular mass index (LVMI) was lower in normotensive patients: 128.3 +/- 46.2 versus 165.8 +/- 46.7 (p < 0.01). The prevalence of LVH was 55% in normotensive HD patients compared to 86% in hypertensive group (p < 0.01). In normotensive group we found correlation between PTH and LVMI (r = 0.44; p < 0.05). There were also significant relationships between calcium and posterior wall thickness (r = -0.44; p < 0.05), phosphorus and LVMI (r = 0.47; p < 0.05). A significant correlation was observed between both phosphorus, calcium x phosphorus product and E/A ratio: r = -0.47 and r = -0.43, respectively (p < 0.05 both). Disturbances of calcium-phosphorus metabolism and secondary hyperparathyroidism contributes to left ventricular hypertrophy, and impaired left ventricular diastolic function in normotensive hemodialysis patients.

MeSH terms

  • Antihypertensive Agents / therapeutic use
  • Blood Pressure
  • Calcium / metabolism*
  • Case-Control Studies
  • Echocardiography
  • Female
  • Humans
  • Hypertension / drug therapy
  • Hypertrophy, Left Ventricular / metabolism*
  • Male
  • Middle Aged
  • Parathyroid Hormone / metabolism*
  • Phosphorus / metabolism*
  • Renal Dialysis*
  • Risk Factors
  • Ventricular Function, Left*


  • Antihypertensive Agents
  • Parathyroid Hormone
  • Phosphorus
  • Calcium